Biology Reference
In-Depth Information
Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K., 2004. Vascular nor-
malization by vascular endothelial growth factor receptor 2 blockade induces a pressure
gradient across the vasculature and improves drug penetration in tumors. Cancer Res.
64, 3731-3736.
Tsung, K., Dolan, J.P., Tsung,Y.L., Norton, J.A., 2002. Macrophages as effector cells in inter-
leukin 12-induced T cell-dependent tumor rejection. Cancer Res. 62, 5069-5075.
Tugues, S., Honjo, S., Konig, C., Noguer, O., Hedlund, M., Botling, J., Deschoemaeker, S.,
Wenes, M., Rolny, C., Jahnen-Dechent, W., Mazzone, M., Claesson-Welsh, L., 2012.
Genetic deficiency in plasma protein HRG enhances tumor growth and metas-
tasis by exacerbating immune escape and vessel abnormalization. Cancer Res. 72,
1953-1963.
van der Bij, G.J., Oosterling, S.J., Meijer, S., Beelen, R.H., van, E.M., 2005a. The role of
macrophages in tumor development. Cell. Oncol. 27, 203-213.
van der Bij, G.J., Oosterling, S.J., Meijer, S., Beelen, R.H., van, E.M., 2005b. Therapeutic
potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology
210, 259-265.
Vosseler, S., Mirancea, N., Bohlen, P., Mueller, M.M., Fusenig, N.E., 2005. Angiogenesis
inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal
matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial
tumor phenotype in surface heterotransplants. Cancer Res. 65, 1294-1305.
Wang, Y.C., He, F., Feng, F., Liu, X.W., Dong, G.Y., Qin, H.Y., Hu, X.B., Zheng, M.H.,
Liang, L., Feng, L., Liang, Y.M., Han, H., 2010. Notch signaling determines the M1
versus M2 polarization of macrophages in antitumor immune responses. Cancer Res.
70, 4840-4849.
Watkins, S.K., Egilmez, N.K., Suttles, J., Stout, R.D., 2007. IL-12 rapidly alters the functional
profile of tumor-associated and tumor-infiltrating macrophages
in vitro
and
in vivo
. J.
Immunol. 178, 1357-1362.
Weichhart, T., Saemann, M.D., 2008. The PI3K/Akt/mTOR pathway in innate immune
cells: emerging therapeutic applications. Ann. Rheum. Dis. 67 (Suppl. 3), iii70-iii74.
Weinmann, M., Jendrossek,V., Handrick, R., Guner, D., Goecke, B., Belka, C., 2004. Molecu-
lar ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial
death pathway in a FADD/caspase-8 independent manner. Oncogene 23, 3757-3769.
Weisshardt, P., Trarbach, T., Durig, J., Paul, A., Reis, H., Tilki, D., Miroschnik, I., Ergun, S.,
Klein, D., 2012. Tumor vessel stabilization and remodeling by anti-angiogenic therapy
with bevacizumab. Histochem. Cell Biol. 137, 391-401.
Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu, L., Hicklin,
D.J., Fukumura, D., di, T.E., Munn, L.L., Jain, R.K., 2004. Kinetics of vascular normaliza-
tion by VEGFR2 blockade governs brain tumor response to radiation: role of oxygen-
ation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.
Wu, H., Xu, J.B., He, Y.L., Peng, J.J., Zhang, X.H., Chen, C.Q., Li, W., Cai, S.R., 2012.
Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric
cancer. J. Surg. Oncol. 106, 462-468.
Xia, J.T., Wang, H., Liang, L.J., Peng, B.G., Wu, Z.F., Chen, L.Z., Xue, L., Li, Z., Li, W., 2012a.
Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic
stage of pancreatic ductal adenocarcinoma. Pancreas 41, 629-635.
Xia, L., Huang, W., Tian, D., Zhu, H., Zhang, Y., Hu, H., Fan, D., Nie, Y., Wu, K., 2012b.
Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor
metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carci-
noma. J. Hepatol. 57, 600-612.
Xu, Y., Jagannath, C., Liu, X.D., Sharafkhaneh, A., Kolodziejska, K.E., Eissa, N.T., 2007. Toll-
like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27,
135-144.
Search WWH ::
Custom Search